Show simple item record

dc.contributor.authorLangley, R E
dc.contributor.authorStephens, R J
dc.contributor.authorNankivell, M
dc.contributor.authorPugh, C
dc.contributor.authorMoore, B
dc.contributor.authorNavani, N
dc.contributor.authorWilson, P
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBarton, R
dc.contributor.authorParmar, M K B
dc.contributor.authorMulvenna, P M
dc.date.accessioned2015-01-21T10:41:08Z
dc.date.available2015-01-21T10:41:08Z
dc.date.issued2013-03
dc.identifier.citationInterim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? 2013, 25 (3):e23-30 Clin Oncol (R Coll Radiol)en
dc.identifier.issn1433-2981
dc.identifier.pmid23211715
dc.identifier.doi10.1016/j.clon.2012.11.002
dc.identifier.urihttp://hdl.handle.net/10541/338583
dc.description.abstractOver 30% of patients with non-small cell lung cancer (NSCLC) develop brain metastases. If inoperable, optimal supportive care (OSC), including steroids, and whole brain radiotherapy (WBRT) are generally considered to be standard care, although there is no randomised evidence demonstrating that the addition of WBRT to OSC improves survival or quality of life.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.subject.meshAged
dc.subject.meshBrain Neoplasms
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCranial Irradiation
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshQuality of Life
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleInterim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?en
dc.typeArticleen
dc.contributor.departmentMRC Clinical Trials Unit, London, UKen
dc.identifier.journalClinical Oncologyen
html.description.abstractOver 30% of patients with non-small cell lung cancer (NSCLC) develop brain metastases. If inoperable, optimal supportive care (OSC), including steroids, and whole brain radiotherapy (WBRT) are generally considered to be standard care, although there is no randomised evidence demonstrating that the addition of WBRT to OSC improves survival or quality of life.


Files in this item

This item appears in the following Collection(s)

Show simple item record